Abstract
The presence of protein inclusions within the central nervous system is a characteristic of most neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Aggregates may induce cell death trough several mechanisms, such as sequestration of essential cellular components, clogging of the proteasome system, and/or disruption of axonal transport. The neuropathological signature of ALS is represented by the presence of ubiquitinated inclusions immunoreactive for the protein TDP-43 in the cytoplasm of motor neurons. Recent studies demonstrated that a significant percentage of familial ALS cases are caused by pathogenic mutations in the TAR DNA binding protein and fused in sarcoma/translocated in liposarcoma genes encoding, respectively, for TDP-43 and FUS proteins. Both TDP-43 and FUS are DNA/RNA-binding proteins involved in transcriptional regulation and splicing, shuttling, maturation and transport of mRNA molecules. Mutations in the two genes seem to induce a nucleo-cytoplasmic redistribution of FUS and TDP-43, possibly promoting aggregate formation and/or disrupting their physiological nuclear functions or their interactions with specific RNA targets. Those findings collectively suggest that alterations in cellular RNA metabolism may trigger motor neuron degeneration.
Keywords: TDP-43, FUS, proteinopathies, motor neuron disease, mRNA metabolism
CNS & Neurological Disorders - Drug Targets
Title: Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
Volume: 9 Issue: 3
Author(s): N. Ticozzi, A. Ratti and V. Silani
Affiliation:
Keywords: TDP-43, FUS, proteinopathies, motor neuron disease, mRNA metabolism
Abstract: The presence of protein inclusions within the central nervous system is a characteristic of most neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Aggregates may induce cell death trough several mechanisms, such as sequestration of essential cellular components, clogging of the proteasome system, and/or disruption of axonal transport. The neuropathological signature of ALS is represented by the presence of ubiquitinated inclusions immunoreactive for the protein TDP-43 in the cytoplasm of motor neurons. Recent studies demonstrated that a significant percentage of familial ALS cases are caused by pathogenic mutations in the TAR DNA binding protein and fused in sarcoma/translocated in liposarcoma genes encoding, respectively, for TDP-43 and FUS proteins. Both TDP-43 and FUS are DNA/RNA-binding proteins involved in transcriptional regulation and splicing, shuttling, maturation and transport of mRNA molecules. Mutations in the two genes seem to induce a nucleo-cytoplasmic redistribution of FUS and TDP-43, possibly promoting aggregate formation and/or disrupting their physiological nuclear functions or their interactions with specific RNA targets. Those findings collectively suggest that alterations in cellular RNA metabolism may trigger motor neuron degeneration.
Export Options
About this article
Cite this article as:
Ticozzi N., Ratti A. and Silani V., Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage, CNS & Neurological Disorders - Drug Targets 2010; 9 (3) . https://dx.doi.org/10.2174/187152710791292585
DOI https://dx.doi.org/10.2174/187152710791292585 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Development of a Non Invasive NGF-Based Therapy for Alzheimers Disease
Current Alzheimer Research Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Fertility Preservation for Young Women with Cancer: Hope for the Future
Current Women`s Health Reviews Mechanisms of Anti-retroviral Drug Resistance: Implications for Novel Drug Discovery and Development
Infectious Disorders - Drug Targets Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued) Monocytes Mediate HIV Neuropathogenesis: Mechanisms that Contribute to HIV Associated Neurocognitive Disorders
Current HIV Research Transcriptome and Proteome Analyses of Drug Interactions with Natural Products
Current Drug Metabolism Cytotoxic Thiol Alkylators
Mini-Reviews in Medicinal Chemistry Glycosyltransferases, Important Tools for Drug Design
Current Topics in Medicinal Chemistry Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Molecular Targets in Gastrointestinal Stromal Tumors (GIST) Therapy
Current Cancer Drug Targets Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Neutrophil Activation Induced by Plant Lectins: Modulation of Inflammatory Processes
Inflammation & Allergy - Drug Targets (Discontinued) Evaluation of Drug Targeting Strategies and Liposomal Trafficking
Current Pharmaceutical Design Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Editorial
Current Medical Imaging